The Carlyle Group agreed to acquire Unchained Labs, a life sciences tools company, for $435m. Management team of Unchained Labs from investment firms Novo Holdings, Canaan Partners and TPG Biotech will also participate in the acquisition. “Unchained Labs sits at the intersection of one of the most attractive sectors in healthcare, life science tools, and its fastest growing end market, biopharma. With strong industry tailwinds, we believe Unchained Labs has significant growth opportunities and we’re excited to support another founder-backed business to scale through investments in research and development, digitization and geographic expansion," Steve Wise, Carlyle Global Head of Healthcare.